Metabolic pathways
Retatrutide
LY3437943
Triple GIP / GLP-1 / glucagon receptor agonist
A next-generation synthetic peptide engineered as a unimolecular triple agonist at the GIP, GLP-1, and glucagon receptors. Actively studied in Phase 2/3 trials and a major object of incretin literature.
For laboratory research use only. Not for human or animal consumption, not a drug, food, cosmetic, or supplement. By adding to cart, the researcher affirms compliance with all applicable regulations.
Vial size
Catalog price
$99
SKU ABL-RET-5
Batch ABL-RET-2604 · Research-use-only checkout required
Specifications
Retatrutide is a synthetic peptide engineered as a balanced agonist at three metabolic receptors simultaneously: GIP, GLP-1, and glucagon. The molecule represents a significant step in the evolution of incretin-pathway tools, extending the dual-agonist concept of Tirzepatide with an added glucagon component intended to engage hepatic and thermogenic pathways.
Published Phase 2 literature has reported substantial effects on body weight, hepatic fat, and glycemic endpoints in study populations with obesity and type 2 diabetes. Phase 3 programs are ongoing as of the most recent publications.
Supplied as a research-grade reference peptide for investigation of triple-agonist incretin pharmacology. Not supplied for therapeutic use.
Related compounds
